Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Tuncay Delibasi has a total of 67 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    When Weight Loss Surgery Meets Hidden Genetics: Lessons from a Case of Post–Bariatric Surgery Hypoglycemia with ABCC8 and GCK Mutation.

    by Uchechi Adeniran, Ibrahim H. Topkaya, Timothy Shope, Melih Kasap, Tuncay Delibasi, Malek El Muayed

  • Open Access

    CNDP1 and Diabetic Kidney Disease: From Genetic Susceptibility to Therapeutic Targeting

    by Bulent Tolga Delibasi, Michael Ismail Sarisen, Matthew Thomas Belitsos, Halil Kutlu Erol, Tuncay Delibasi

    Diabetic kidney disease (DKD) affects a substantial proportion of individuals with diabetes mellitus and represents the leading cause of end-stage renal disease worldwide. Familial aggregation studies consistently demonstrate that genetic factors contribute significantly to DKD susceptibility beyond metabolic and hemodynamic determinants. The carnosine dipeptidase 1 (CNDP1) gene on chromosome 18q22.3 has emerged as a compelling susceptibility locus, with a trinucleotide (CTG) repeat polymorphism in exon 2 that encodes the Mannheim variant, which has demonstrated protective associations in selected populations. Individuals homozygous for the shorter (CTG)5 allele exhibit reduced serum carnosinase-1 concentrations and activity, resulting in elevated tissue carnosine levels. Carnosine exerts multiple renoprotective effects, including antioxidant activity, inhibition of advanced glycation end-product formation, and attenuation of profibrotic signaling. Experimental models demonstrate that genetic or pharmacological reduction in carnosinase activity attenuates diabetic kidney injury. Early clinical studies of carnosine supplementation report improvements in albuminuria and oxidative stress markers, though available trials are limited in size, duration, and population scope. Therapeutic targeting of CNDP1 via carnosinase inhibition, therefore, represents a biologically grounded yet still emerging pharmacological strategy. This review synthesizes genetic, molecular, and translational evidence supporting CNDP1 as a model for genetics-informed therapeutic development in DKD, while highlighting important population-specific variation in allele frequencies that constrain universal clinical applicability.

  • Targeting Inflammation in Type 2 Diabetes: The Role of Colchicine

    by Sevket Ercan Tunc, Bulent Tolga Delibasi, Tuncay Delibasi

    Type 2 diabetes mellitus (T2DM) remains one of the most prevalent chronic metabolic disorders globally, presenting an ongoing challenge in terms of prevention and management. The majority of existing therapeutic strategies focus primarily on glycemic control. However, the role of inflammation in the pathogenesis of the disease is being recognized increasingly, which has brought to light a critical gap in our understanding of diabetes treatment in the context of anti-inflammatory therapeutics. Inflammatory reactions are essential to the development and progression of T2DM. The NLRP3 inflammasome, along with its downstream inflammatory factors, is a key mediator of these responses. Recent data underscore the significance of Interleukin-1β (IL-1β) in instigating and sustaining inflammation-related organ dysfunction in T2DM. Consequently, factors governing NLRP3 activation and IL-1β expression emerge as potential therapeutic targets. Here, we aim to examine one such therapeutic agent, colchicine, which can potentially manage inflammation associated with T2DM. As an anti-inflammatory medicine, colchicine can inhibit the assembly and activation of the NLRP3 inflammasome via various mechanisms, thereby mitigating inflammation. In this context, the study discusses the mechanisms that link metabolic disorders with the onset of chronic inflammation, evaluates clinical studies and trials that investigate the efficacy and safety of colchicine, as well as discusses its benefits and limitations as an anti-inflammatory therapy in T2DM. The goal is to provide a clear framework for understanding the role of colchicine in the therapeutic landscape of T2DM, potentially leading to novel approaches for managing the disease.


  • Open Access

    β-Catenin stabilization protects against alveolar hemorrhage through amphiregulin- and BATF-mediated Tregs

    by Fiona Mason, Hui Xiong, Ali Mobeen, Saddam Hossain, Sara Mahmudlu, Rosanne Trevail, Mikyal Mobeen, Li Chen, Sunny Lee, Tuncay Delibasi, et al.

    Alveolar hemorrhage (AH) is a life-threatening condition with high mortality, yet the immunological mechanisms governing disease severity remain poorly defined. Here, we demonstrate a protective role for T cell–intrinsic β-catenin stabilization in AH using a transgenic mouse model (CAT-Tg) in which β-catenin is stabilized under the Lck promoter. We found β-catenin stabilization induced a distinct T cell phenotype marked by expansion of central effector memory cells (CD44 + CD122 + Eomes + T-bet + ) and suppression of proinflammatory signaling, including reduced phosphorylation of STAT1, STAT3, and JAK1. Pristane-induced AH was attenuated in CAT-Tg mice, which exhibited reduced lung injury, decreased proteinuria, and diminished pulmonary proinflammatory cytokine production compared with WT controls. Protection was associated with a marked expansion of FOXP3 + Tregs. Mechanistically, β-catenin stabilization enhanced lung expression of amphiregulin and BATF, mediators of Treg stability and tissue repair. Adoptive transfer of CAT-Tg–derived Tregs into WT mice conferred superior protection against AH, reducing lung inflammation and proteinuria. Transcriptomic analyses revealed enrichment of tissue repair and immune homeostasis pathways, including PI3K-Akt, angiogenesis, and STAT5 signaling. Collectively, these findings identify β-catenin as a regulator of a protective amphiregulin/BATF/Treg axis, highlighting an immunomodulatory pathway with therapeutic potential for AH and inflammatory lung disease.


  • The relationship between cytotoxin-associated gene A positiveHelicobacter pyloriinfection and autoimmune thyroid disease

    by Muyesser Sayki Arslan, Fuat Ekiz, Murat Deveci, Mustafa Sahin, Oya Topaloglu, Basak Karbek, Esra Tutal, Zeynep Ginis, Erman Cakal, Mustafa Ozbek, et al.

    The aim of this study was to determine whether there is an association between cagA [cytotoxin-associated gene A] positivity and thyroid autoimmunity and thyroid volume. This prospective study included 78 Helicobacter pylori-positive (H. pylori) dyspeptic patients in the study group, and 50 age-, gender-, and body mass index-matched H. pylori-negative dyspeptic patients in the control group. All the controls were evaluated via upper gastrointestinal endoscopic biopsy or breath test, and were found as H. pylori negative. Gastric biopsy specimens were obtained via endoscopy and histological examination was performed for documentation of H. pylori. In all, 55.1% (n = 43) of the H. pylori-positive patients were cagA positive. There was no significant difference in metabolic syndrome parameters or thyroid function test results between the study and control groups. The frequency of anti-TPO and Hashimoto's thyroiditis positivity was significantly higher in the study group than in the control group. Thyroid volume was higher and severe parenchymal heterogeneity was more common in the H. pylori-positive patients. H. pylori infection might be a risk factor for autoimmune thyroid disease and high thyroid volume in patients diagnosed with histological evaluation. However, cagA positivity has no additional effect on these parameters.


  • Open Access

    Evaluation of serum vitamin D levels in elderly patients with subclinical hypothyroidism

    by Fatma Uçar, Sümeyya Akyol, Gulfer Ozturk, Zeynep Ginis, Gonul Erden, Mine Yavuz Taslipinar, Abdullah Ercan Arzuhal, Tuncay Delibası

    Evaluation of serum vitamin D levels in elderly patients with subclinical hypothyroidism


  • Open Access

    Permanent central diabetes insipidus as a complication of sphenoid sinus mucocele

    by Güleser Saylam, Ömer Bayır, Derya Girgin, Müyesser Saykı Arslan, Emel Çadallı Tatar, Ali Özdek, Tuncay Delibaşı, Mehmet Hakan Korkmaz


  • Protection from cylophosfamid induced ovarian damage with bone marrow derived mezenchymal stem cells

    by S. Kilic, F. Pinarli, C. Ozogul, N. Tasdemir, G.N. Sarac, T. Delibasi

  • Cellular Immunity Before and After Leptin Replacement Therapy

    by G.J. Paz-Filho, T. Delibasi, H.K. Erol, M.-L. Wong, J. Licinio

    The few identified leptin-deficient children have immune deficiency. To evaluate whether a newly-identified leptin-deficient boy has immune defects; to assess the immune changes during leptin replacement. A 5 year-old boy with congenital leptin deficiency was evaluated before, 2 weeks and 6 weeks after the initiation of recombinant methionyl human leptin. Thymic volume was measured by computed tomography. Humoral immunity was assessed by measuring levels of several immunoglobulins. Cellular immunity was evaluated by the analysis of lymphocyte proliferation in response to mitogens. Lymphocyte subsets were quantified by flow cytometry. At baseline, thymic volume was increased. The lymphocyte subsets count and humoral/cellular immunities were normal. After treatment, proliferative response to mitogens increased by 1.5- to 3-fold, and lymphocyte count decreased by 17%. Immune defects are not an obligatory feature of congenital leptin deficiency. Even in the absence of significant immune defects, leptin replacement therapy enhanced T-cell responsiveness.


  • Open Access

    The major clinical outcomes of diabetic foot infections: One center experience

    by Adem Ozkara, Tuncay Delibası, Yusuf Selcoki, Mehmet Fettah Arikan

    Diabetes mellitus with its limb and life-threatening complications such as diabetic foot infection and amputation are increasing at epidemic rates all over the world. The objective of this study was to determine the rate of lower extremity amputation, the risk factors and the bacteriologic profile for diabetic foot lesions. The records of all 84 patients with diabetic foot infections of a large general hospital over a 4-year period were retrospectively included. The most commonly isolated pathogens were Staphylococcus aureus (39%), Pseudomonas aeruginosa (14%), Proteus mirabilis (14%), Escherichia coli (14%), Group B streptococci (12%), and Klebsiella pneumonia (8%). The variables, independently associated with higher foot infections, were inadequate diabetic regulation (93%), peripheral neuropathy (88.1%), peripheral vascular disease (73.8%), smoking (56%), past history of ulcer (28.5%), penetrating injury (20.3%), inadequate foot wear (15%) and Charcot osteoartropathy (10.7%). The general amputation rate was 38.1%. Diabetic foot ulcers and its complication rates including infection, gangrene and lower extremity amputation in Turkey are still high. Preventive care of the foot in patients with diabetes mellitus is extremly important. Therefore early diagnosing of risk factors for diabetic foot infections in the primary care setting and their adequate therapy under multidisciplinary approach should not be neglected.